Peter C. Richardson

Insider Reports History

Location
Valencia, CA
Signature
/s/ Mark Tyndall, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Peter C. Richardson:

Form 4 holding EVP & Chief Scientific Officer

Mallinckrodt plc

Security class
Restricted Stock Units
Shares / value
27,357
Estimated value
Report date
31 Jul 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding EVP & Chief Scientific Officer

Mallinckrodt plc

Security class
Ordinary Shares
Shares / value
3,419
Estimated value
Report date
01 Jan 2025
Price
$37.50
Ownership
Direct
Form 4 holding EVP, Research and Development and Chief Medical Officer

ANTARES PHARMA, INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
24 May 2022
Price
$5.60
Ownership
Direct
Form 4 holding EVP, Research and Development and Chief Medical Officer

ANTARES PHARMA, INC.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
24 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Peter C. Richardson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .